D-Mannose (Urinary Tract Support Monosaccharide)
| CAS No. | 3458-28-4 |
| Class | Carbohydrate · Monosaccharide · Aldohexose |
| Source | Commercially: enzymatic isomerisation of glucose; naturally present in cranberry, apple, guar bean |
| Claim strength | High |
| Buy from Herbuno | D-Mannose 99% Powder → |
D-Mannose is a simple six-carbon sugar — the C-2 epimer of glucose — with an unusual property: approximately 90% of ingested D-mannose is excreted unchanged in the urine rather than metabolised. This makes it pharmacologically active in the urinary tract rather than systemically, which is the basis for its documented role in urinary tract infection prevention. It is one of the most commercially significant non-antibiotic UTI management ingredients in the supplement market.
D-Mannose for Urinary Tract Health & UTI Prevention — Clinical Evidence
Mechanism — competitive inhibition of bacterial adhesion: Uropathogenic Escherichia coli — responsible for approximately 80% of uncomplicated UTIs — attaches to bladder wall uroepithelial cells via mannose-binding type 1 fimbriae. Supplemental D-mannose saturates these fimbriae binding sites in the urine, preventing bacterial attachment to the bladder wall. Bacteria are flushed from the urinary tract with normal urination. The mechanism is physical displacement — not antimicrobial activity — which means no antibiotic resistance development.
RCT evidence — non-inferior to prophylactic antibiotics: A landmark 2014 RCT (Kranjčec et al.) compared D-mannose 2g daily to nitrofurantoin prophylaxis and placebo over six months in women with recurrent UTI. D-mannose produced a statistically significant reduction in UTI recurrence versus placebo (14.6% vs 60.8% recurrence rate) and was non-inferior to nitrofurantoin with significantly fewer side effects. This single trial established D-mannose as the most evidence-supported non-antibiotic UTI prevention supplement available.
Blood glucose impact — minimal: Unlike glucose, D-mannose has minimal effect on blood insulin levels at standard supplement doses — approximately 90% is excreted unchanged in the urine within hours. This makes it appropriate for use in diabetic and insulin-sensitive populations, where UTI risk is elevated and antibiotic alternatives are particularly commercially relevant.
D-Mannose Dosage, Format & Formulator Specification
Standard dose: 2g once daily for UTI prevention (the dose used in the landmark RCT). For acute UTI management, some protocols use 2g three times daily for three days then once daily for 10 days — always alongside medical supervision. Powder sachet dissolved in water is the dominant commercial format — D-mannose is tasteless to mildly sweet and fully water-soluble, requiring no flavour masking.
99% purity — specify this grade: At 99% purity, dose accuracy is precise. Lower purity grades contain glucose and other monosaccharide impurities — relevant for diabetic-positioning products where glucose content on the label matters. Confirm purity by HPLC on the CoA.
Stability: D-mannose is highly stable under standard storage conditions — 24+ month shelf life at ambient temperature. No cold chain requirement. Compatible with standard capsule, sachet, and tablet manufacturing without special handling.
Pairs with: Cranberry extract PAC fraction (complementary UTI mechanism — PAC inhibits type P fimbriae while D-mannose targets type 1 fimbriae), hibiscus extract (urinary tract comfort), vitamin C (urinary acidification).
Frequently Asked Questions — D-Mannose
How does D-mannose prevent UTIs?
D-mannose works by competitive inhibition — uropathogenic E. coli uses mannose-binding fimbriae to attach to bladder wall cells. Supplemental D-mannose saturates these binding sites in the urine, preventing bacterial adhesion. Bacteria are flushed out with normal urination. The mechanism is physical displacement rather than antimicrobial activity — no antibiotic resistance risk.
Is D-mannose safe for people with diabetes?
D-mannose has minimal impact on blood glucose and insulin at standard supplement doses — approximately 90% is excreted unchanged in urine rather than metabolised. It is generally considered appropriate for diabetic populations at standard doses. However, individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should exercise caution as mannose metabolism may be impaired. Medical supervision is advisable for diabetic individuals using D-mannose regularly.
Can D-mannose treat an active UTI or only prevent recurrence?
D-mannose is best evidence-supported for prevention of recurrent UTI rather than treatment of active infection. The Kranjčec 2014 RCT studied prevention over six months. For an active UTI with symptoms, medical evaluation and appropriate treatment are required — D-mannose should not replace medical care for symptomatic infection.
What is the difference between D-mannose and cranberry extract for UTI?
Different mechanisms targeting different bacterial attachment pathways. D-mannose targets type 1 fimbriae (mannose-binding). Cranberry proanthocyanidins (PAC fraction) target type P fimbriae (different attachment pathway). The two can be combined for complementary coverage. D-mannose has stronger and more direct clinical evidence from RCTs. Cranberry PAC has a longer commercial history but more variable evidence quality.